Consistent with previous research, their findings demonstrate that disabling PERK signaling hinders the clonogenic and growth abilities of CML cells and amplifies apoptosis triggered by imatinib [34]. This evidence concerns the gene EIF2AK3 and chronic myelogenous leukemia, BCR-ABL1 positive.